Allegiance Financial Group Advisory Services LLC Acquires 3,076 Shares of Johnson & Johnson (NYSE:JNJ)

Allegiance Financial Group Advisory Services LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 92.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,405 shares of the company's stock after purchasing an additional 3,076 shares during the period. Allegiance Financial Group Advisory Services LLC's holdings in Johnson & Johnson were worth $1,062,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Lantz Financial LLC lifted its stake in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $453,000. Joel Isaacson & Co. LLC raised its position in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. State of Wyoming lifted its stake in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC boosted its holdings in shares of Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $172.87.

Johnson & Johnson Stock Up 0.5%

Shares of NYSE JNJ traded up $0.75 during trading on Monday, hitting $164.45. The stock had a trading volume of 3,456,993 shares, compared to its average volume of 9,093,110. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a fifty day moving average of $154.29 and a two-hundred day moving average of $155.12. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $395.68 billion, a PE ratio of 17.59, a PEG ratio of 2.08 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the company posted $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.16%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.